Table 1.

Serum samples in which the prevalence of neutralizing antibodies (NAbs) against adeno-associated virus (AAV) 1, AAV7, or AAV8 exceeded the prevalence of anti-AAV2 NAb.

Region	AAV1, % of samples	AAV7, % of samples	AAV8, % of samples
Australia	11	6	2
Europe
Belgium	6	3	3
Greece	17	1	1
Italy	3	2	4
Africa
Uganda	12	4	7
Rwanda	18	10	11
South Africa	30	4	5
Kenya	21	6	11
Zambia	14	8	1
United States	13	10	5

NOTE. Data indicate the percentage of samples in which anti-AAV1, anti-AAV7, or anti-AAV8 Nab titers were >1:20 and anti-AAV2 NAb titers were <1:20.